Effects of sitagliptin on 24-H glycemic changes in japanese patients with type 2 diabetes assessed using continuous glucose monitoring

Diabetes Technology and Therapeutics

Volumn 13, Issue 7, 2011, Pages 699-703

  Mori, Yutaka ^a   Taniguchi, Yukiko ^b   Matsuura, Kenichi ^a   Sezaki, Kazunori ^b   Yokoyama, Junichi ^a   Utsunomiya, Kazunori ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shin Yamanote Hospital   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN;

AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; MONITORING, AMBULATORY; PILOT PROJECTS; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES;

EID: 79959651989     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0025     Document Type: Article

References (20)

1. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621
2. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077 (Pubitemid 34680970)
3. International Diabetes Federation: Guideline for Management of Postmeal Glucose. www.idf.org/guideline-postmeal (accessed March 2008)
4. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCannME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2- amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48:141-151 (Pubitemid 40105255)
5. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, TanakaW, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619 (Pubitemid 44833446)
6. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688 (Pubitemid 41773643)
7. Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson- Levonas AO, Amatruda JM: Effects of once daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009;41:232-237
8. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM: Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12:613-622
9. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 (Pubitemid 46048557)
10. Nagashima K, Inagaki N: Progress in therapy for diabetes mellitus-insulin-secretion inducing oral hypoglycemic agents [in Japanese]. Nippon Naika Gakkai Zasshi 2009;98: 737-741
11. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52 (Pubitemid 16162741)
12. Mori Y: Continuous glucose monitoring (CGM) [in Japanese]. J Ther 2010;92:569-576
13. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE: Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-1243
14. Drucker DJ: The biology of incretin hormones. Cell Metab 2006;3:153-165
15. Buteau J: GLP-1 receptor signaling: effects on pancreatic betacell proliferation and survival. Diabetes Metab 2008;34(Suppl 2):S73-S77 (Pubitemid 351978286)
16. Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439 (Pubitemid 350041474)
17. Sandoval D: CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav 2008;94:670-674 (Pubitemid 351850235)
18. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM: Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-451
19. Aschner P, Katzeff HL, Guo H, Sunga S,Williams-Herman D, Kaufman KD, Goldstein BJ: Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-261
20. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J: Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57: 383-394